Nuvation Bio upgraded by Jefferies with a new price target
$NUVB
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Nuvation Bio from Hold to Buy and set a new price target of $10.00 from $1.40 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2025 | Buy | Truist | |
| 11/19/2025 | $12.00 | Buy | B. Riley Securities |
| 9/30/2025 | $10.00 | Buy | Jefferies |
| 4/23/2025 | $6.00 | Mkt Outperform | Citizens JMP |
| 3/27/2024 | $1.40 → $10.00 | Hold → Buy | Jefferies |
| 3/26/2024 | $5.00 | Neutral → Buy | BTIG Research |
| 1/6/2023 | $5.00 → $2.00 | Buy → Hold | Jefferies |
| 8/2/2022 | $8.00 → $2.50 | Outperform → Market Perform | BMO Capital Markets |
Truist initiated coverage of Nuvation Bio with a rating of Buy
B. Riley Securities initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $12.00
Jefferies initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $10.00
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
25-NSE - Nuvation Bio Inc. (0001811063) (Subject)
8-K - Nuvation Bio Inc. (0001811063) (Filer)
144 - Nuvation Bio Inc. (0001811063) (Subject)
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the fourth quarter and full year of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 17, 2026 /CNW/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies representing the fastest-growing subsegment and over 100 antibody-drug conjugates now in active clinical development[1]. That pipeline depth extends to radiopharmaceuticals, cell therapies, and device-based platforms now generating survival data in tumor types that have resisted conventional approaches for decades. Oncolytics Biotech Inc. (NASDAQ:ONCY), Novocure (NASDAQ:NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ:IBRX), and Nuvation Bio Inc. (N
Protocol amendment to change SIGMA from a Phase 2 to a Phase 3 study now complete The currently enrolling SIGMA trial will now include patients with grade 2 astrocytoma with high-risk features in the maintenance setting, in addition to previously eligible patients with high-grade astrocytoma A new exploratory cohort has also been added for patients with grade 3 oligodendroglioma in the post-surgical setting Broad patient population in SIGMA represents most forms of IDH1-mutant glioma that do not have an FDA-approved targeted treatment option Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announc
NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the fourth quarter and full year of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +
Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's unprecedented durability in TKI-naïve, advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) increased to 50 months as of August 2025 Enrolled first patient in global, randomized study of safusidenib with registrational intent for maintenance treatment of high-grade IDH1-mutant glioma Enrolled first patient in TRUST-IV phase 3 study of IBTROZI for the adjuvant treatment of ROS1+ early-stage NSCLC Strong balance sheet with cash, cash equivalents, and marketable securities of $549.0 million as of Septembe
Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 405112. An archived recording will be available on Nuvation Bio's website for 90 days following the event. A
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
4 - Nuvation Bio Inc. (0001811063) (Issuer)
Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha
Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage
Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t
SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)
SC 13D - Nuvation Bio Inc. (0001811063) (Subject)